Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank

Aravinthan Loganathan,Giovanni Zanframundo,Akira Yoshida,Sara Faghihi-Kashani,Iazsmin Bauer Ventura,Eduardo Dourado,Francisca Bozan,Gianluca Sambataro,Yasuhiko Yamano,Sharon Sangmee Bae,Darosa Lim,Angela Ceribelli,Natasa Isailovic,Carlo Selmi,Noreen Fertig,Elena Bravi,Yuko Kaneko,André Pinto Saraiva,Vega Jovani,Javier Bachiller-Corral,Jose Cifrian,Antonio Mera-Varela,Siamak Moghadam-Kia,Veronica Wolff,Julien Campagne,Alain Meyer,Margherita Giannini,Konstantinos Triantafyllias,Johannes Knitza,Latika Gupta,Yair Molad,Florenzo Iannone,Ilaria Cavazzana,Matteo Piga,Giacomo De Luca,Sarah Tansley,Emanuele Bozzalla-Cassione,Francesco Bonella,Tamera J Corte,Tracy J Doyle,David Fiorentino,Miguel Angel Gonzalez-Gay,Marie Hudson,Masataka Kuwana,Ingrid E Lundberg,Andrew L Mammen,Neil John McHugh,Fredrick W Miller,Carlomaurizio Montecucco,Chester V Oddis,Jorge Rojas-Serrano,Jens Schmidt,Carlo Alberto Scirè,Albert Selva-O'Callaghan,Victoria P Werth,Claudia Alpini,Sara Bozzini,Lorenzo Cavagna,Rohit Aggarwal,Tamera J. Corte,Tracy J. Doyle,Ingrid E. Lundberg,Andrew L. Mammen,Fredrick W. Miller,Chester V. Oddis,Victoria P. Werth

DOI: https://doi.org/10.55563/clinexprheumatol/s14zq8

2024-03-14

Clinical and Experimental Rheumatology

Abstract:OBJECTIVES: The CLASS (Classification Criteria of Anti-Synthetase Syndrome) project is a large international multicentre study that aims to create the first data-driven anti-synthetase syndrome (ASSD) classification criteria. Identifying anti-aminoacyl tRNA synthetase antibodies (anti-ARS) is crucial for diagnosis, and several commercial immunoassays are now available for this purpose. However, using these assays risks yielding false-positive or false-negative results, potentially leading to misdiagnosis. The established reference standard for detecting anti-ARS is immunoprecipitation (IP), typically employed in research rather than routine autoantibody testing. We gathered samples from participating centers and results from local anti-ARS testing. As an "ad-interim" study within the CLASS project, we aimed to assess how local immunoassays perform in real-world settings compared to our central definition of anti-ARS positivity.METHODS: We collected 787 serum samples from participating centres for the CLASS project and their local anti-ARS test results. These samples underwent initial central testing using RNA-IP. Following this, the specificity of ARS was reconfirmed centrally through ELISA, line-blot assay (LIA), and, in cases of conflicting results, protein-IP. The sensitivity, specificity, positive likelihood ratio and positive and negative predictive values were evaluated. We also calculated the inter-rater agreement between central and local results using a weighted κ co-efficient.RESULTS: Our analysis demonstrates that local, real-world detection of anti-Jo1 is reliable with high sensitivity and specificity with a very good level of agreement with our central definition of anti-Jo1 antibody positivity. However, the agreement between local immunoassay and central determination of anti-non-Jo1 antibodies varied, especially among results obtained using local LIA, ELISA and "other" methods.CONCLUSIONS: Our study evaluates the performance of real-world identification of anti-synthetase antibodies in a large cohort of multi-national patients with ASSD and controls. Our analysis reinforces the reliability of real-world anti-Jo1 detection methods. In contrast, challenges persist for anti-non-Jo1 identification, particularly anti-PL7 and rarer antibodies such as anti-OJ/KS. Clinicians should exercise caution when interpreting anti-synthetase antibodies, especially when commercial immunoassays test positive for non-anti-Jo1 antibodies.

rheumatology